Single-Dose HPV Vaccine: Boosting Cervical Cancer Prevention in Resource-Constrained Settings

Single-Dose HPV Vaccination Latest Updates: Cervical Cancer Prevention Efforts

1. HPV Vaccine Single-Dose Usage: A New Milestone in Cervical Cancer Prevention

The World Health Organization (WHO) has announced the prequalification of the HPV vaccine product, Cecolin®, for use in a single-dose schedule. This decision is based on new data that meets the WHO’s criteria for alternative, off-label use of HPV vaccines in single-dose schedules[1].

2. Efficacy of Single-Dose HPV Vaccines

Studies have shown that a single dose of the HPV vaccine is highly effective in protecting young women against cervical infections caused by cancer-causing HPV types. For instance, a study in Kenya demonstrated that a single dose of the bivalent HPV vaccine provided 97.5% protection against persistent infections with HPV 16 and 18, the two types that cause approximately 70% of all cervical cancers[3].

3. Global Efforts to Increase HPV Vaccine Coverage

To accelerate the elimination of cervical cancer, global data indicates an increase in one-dose HPV vaccine coverage among girls aged 9-14 from 20% in 2022 to 27% in 2023. By 2024, 57 countries were implementing the single-dose schedule, reaching at least 6 million additional girls with the vaccine in 2023[1].

4. Financial Commitment and Challenges

Despite progress, significant financial and production challenges have hindered HPV vaccine introductions since 2018. A nearly $600 million commitment from various donors, including the Bill & Melinda Gates Foundation and the World Bank, aims to boost HPV vaccine coverage among girls by 2030[1].

5. Single-Dose Recommendation and Implementation

WHO recommends using a single-dose or two-dose schedule for primary HPV vaccination in girls aged 9-14 and young women aged 15-20. This approach simplifies vaccination logistics, reduces costs, and enables more girls worldwide to receive the life-saving vaccine[4].

By leveraging single-dose HPV vaccination, efforts are being made to eliminate cervical cancer, particularly in resource-constrained settings where vaccine access has been low. The adoption of a single-dose schedule has the potential to accelerate global vaccination efforts and bring us closer to achieving the goal of having 90% of girls vaccinated by 15 years of age by 2030[1, 4].